Catalent (CTLT), Novo Nordisk (NVO) receive second request from FTC

Go back to Catalent (CTLT), Novo Nordisk (NVO) receive second request from FTC

Buy the dip in this major pharma stock - Citi

May 6, 2024 9:30 AM EDT

Citi analysts said in a note Monday that they believe history shows the dip in one major pharmaceutical company's shares should be bought.

The investment bank said Novo Nordisk (NYSE: NVO) remains Buy-rated, while the firm also maintained a Dkr975.00 price target on the stock.... More